Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Deferred Revenue: 2021-2022

Historic Current Deferred Revenue for Autolus Therapeutics (AUTL) over the last 2 years, with Dec 2022 value amounting to $35.0 million.

  • Autolus Therapeutics' Current Deferred Revenue fell 96.26% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 96.26%. This contributed to the annual value of $35.0 million for FY2022, which is 25.53% down from last year.
  • As of FY2022, Autolus Therapeutics' Current Deferred Revenue stood at $35.0 million, which was down 25.53% from $47.0 million recorded in FY2021.
  • In the past 5 years, Autolus Therapeutics' Current Deferred Revenue ranged from a high of $47.0 million in FY2021 and a low of $35.0 million during FY2022.
  • Over the past 2 years, Autolus Therapeutics' median Current Deferred Revenue value was $41.0 million (recorded in 2021), while the average stood at $41.0 million.
  • Data for Autolus Therapeutics' Current Deferred Revenue shows a maximum YoY dropped of 25.53% (in 2022) over the last 5 years.
  • Yearly analysis of 2 years shows Autolus Therapeutics' Current Deferred Revenue stood at $47.0 million in 2021, then decreased by 25.53% to $35.0 million in 2022.